Literature DB >> 1863023

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

G E D'Alonzo1, R J Barst, S M Ayres, E H Bergofsky, B H Brundage, K M Detre, A P Fishman, R M Goldring, B M Groves, J T Kernis.   

Abstract

OBJECTIVE: To characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival.
DESIGN: Registry with prospective follow-up.
SETTING: Thirty-two clinical centers in the United States participating in the Patient Registry for the Characterization of Primary Pulmonary Hypertension supported by the National Heart, Lung, and Blood Institute. PATIENTS: Patients (194) diagnosed at clinical centers between 1 July 1981 and 31 December 1985 and followed through 8 August 1988. MEASUREMENTS: At diagnosis, measurements of hemodynamic variables, pulmonary function, and gas exchange variables were taken in addition to information on demographic variables, medical history, and life-style. Patients were followed for survival at 6-month intervals. MAIN
RESULTS: The estimated median survival of these patients was 2.8 years (95% Cl, 1.9 to 3.7 years). Estimated single-year survival rates were as follows: at 1 year, 68% (Cl, 61% to 75%); at 3 years, 48% (Cl, 41% to 55%); and at 5 years, 34% (Cl, 24% to 44%). Variables associated with poor survival included a New York Heart Association (NYHA) functional class of III or IV, presence of Raynaud phenomenon, elevated mean right atrial pressure, elevated mean pulmonary artery pressure, decreased cardiac index, and decreased diffusing capacity for carbon monoxide (DLCO). Drug therapy at entry or discharge was not associated with survival duration.
CONCLUSIONS: Mortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index. Such an equation, once validated prospectively, could be used as an adjunct in planning treatment strategies and allocating medical resources.

Entities:  

Mesh:

Year:  1991        PMID: 1863023     DOI: 10.7326/0003-4819-115-5-343

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  798 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 2.  Primary pulmonary hypertension: the pressure rises for a gene.

Authors:  J R Thomson; R C Trembath
Journal:  J Clin Pathol       Date:  2000-12       Impact factor: 3.411

3.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

4.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.

Authors:  Athénaïs Boucly; Jason Weatherald; Laurent Savale; Xavier Jaïs; Vincent Cottin; Grégoire Prevot; François Picard; Pascal de Groote; Mitja Jevnikar; Emmanuel Bergot; Ari Chaouat; Céline Chabanne; Arnaud Bourdin; Florence Parent; David Montani; Gérald Simonneau; Marc Humbert; Olivier Sitbon
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

5.  Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension.

Authors:  Gabriela Querejeta Roca; Patricia Campbell; Brian Claggett; Ali Vazir; Debbie Quinn; Scott D Solomon; Amil M Shah
Journal:  Eur J Heart Fail       Date:  2014-11-04       Impact factor: 15.534

6.  Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension.

Authors:  Anna R Hemnes; Aaron W Trammell; Stephen L Archer; Stuart Rich; Chang Yu; Hui Nian; Niki Penner; Mitchell Funke; Lisa Wheeler; Ivan M Robbins; Eric D Austin; John H Newman; James West
Journal:  Circulation       Date:  2014-10-31       Impact factor: 29.690

7.  Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension.

Authors:  Veronika Wetzl; Svenja Lena Tiede; Lothar Faerber; Norbert Weissmann; Ralph Theo Schermuly; Hossein Ardeschir Ghofrani; Henning Gall
Journal:  Lung       Date:  2017-05-17       Impact factor: 2.584

8.  Right ventricular to left ventricular diameter ratio at end-systole in evaluating outcomes in children with pulmonary hypertension.

Authors:  Pei-Ni Jone; Julie Hinzman; Brandie D Wagner; David Dunbar Ivy; Adel Younoszai
Journal:  J Am Soc Echocardiogr       Date:  2013-12-08       Impact factor: 5.251

Review 9.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

10.  Epoprostenol treatment of acute pulmonary hypertension is associated with a paradoxical decrease in right ventricular contractility.

Authors:  Steffen Rex; Carlo Missant; Patrick Segers; Rolf Rossaint; Patrick F Wouters
Journal:  Intensive Care Med       Date:  2007-08-21       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.